A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
The Pan American Health Organization, which is the World Health Organization’s agency for the Americas, has adopted a regional plan of action on demen...
Accessiblity Issues, Disabilities, Health and Wellness, Managed Risk
Bed Handles Inc. has once again announced a recall of its adult portable bed handles due to serious entrapment and strangulation hazards as it has rec...
Health and Wellness, Health Care, Managed Risk
A panel of the Food and Drug Administration has voted to recommend approval of a new flu vaccine designed for older adults. It would be the first s...
Facts and Figures, Health and Wellness, Medication Management, Memory Care Best Practices and Research, Memory Care Education, Reports
A large, national clinical trial to study the effect of resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomark...
The Internet-security focused (ISC)˛ Foundation has unveiled a program designed to educate older adults about the importance of cyber security.
All About Alzheimer’s: Receptor Drug Success, Gene Signatures, Type 2 Diabetes, and Expanding Waistlines
There are currently five medications approved by the FDA to treat Alzheimer’s disease but these drugs mask the symptoms rather than stop the disease f...
Business, CEO, cheatsheet, Clinical Quality and Quality Care Delivery, Human Resources and Organizational Development, Public Policy
Join fellow members of ALFA’s Executive Roundtables and President’s Council at the annual Senior Living Executive Forum, Oct. 21-22 at the Omni Rancho...
Falls Prevention, Managed Risk
The National Council on Aging has released its 2015 Falls Prevention Action Plan, a roadmap for a coordinated efforts to reduce falls over the next de...
End of Life, Engage, Managed Risk, Membership, Memory Care Best Practices and Research, Memory Care Education
The Alzheimer’s Foundation of America has announced that National Memory Screening Week will take place the first week of November and participating s...
Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, Reports
There are currently about 46.8 million people around the globe living with dementia with those figures expected to nearly double every 20 years, find...